Cytokeratin 19 expression in intrathoracic neoplasms: First study utilizing cellblocks, evaluating the role of a rarely used cytokeratin for lung cancers

2022 ◽  
Author(s):  
Vikrant Verma ◽  
Ram Nawal Rao
Keyword(s):  
Cytokeratin 19 ◽  
Lung Cancers

scholarly journals The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3711
Author(s):  
François Montagne ◽  
Florian Guisier ◽  
Nicolas Venissac ◽  
Jean-Marc Baste
Keyword(s):  
Lung Cancer ◽  
Residual Disease ◽  
State Of The Art ◽  
Locally Advanced ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Screening Programs ◽  
Systemic Therapies

Non-small cell lung cancers (NSCLC) are different today, due to the increased use of screening programs and of innovative systemic therapies, leading to the diagnosis of earlier and pre-invasive tumors, and of more advanced and controlled metastatic tumors. Surgery for NSCLC remains the cornerstone treatment when it can be performed. The role of surgery and surgeons has also evolved because surgeons not only perform the initial curative lung cancer resection but they also accompany and follow-up patients from pre-operative rehabilitation, to treatment for recurrences. Surgery is personalized, according to cancer characteristics, including cancer extensions, from pre-invasive and local tumors to locally advanced, metastatic disease, or residual disease after medical treatment, anticipating recurrences, and patients’ characteristics. Surgical management is constantly evolving to offer the best oncologic resection adapted to each NSCLC stage. Today, NSCLC can be considered as a chronic disease and surgery is a valuable tool for the diagnosis and treatment of recurrences, and in palliative conditions to relieve dyspnea and improve patients’ comfort.

scholarly journals Targeting HSPA1A in ARID2-deficient lung adenocarcinoma

2021 ◽  
Author(s):  
Xue Wang ◽  
Yuetong Wang ◽  
Zhaoyuan Fang ◽  
Hua Wang ◽  
Jian Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Genetically Engineered ◽  
Malignant Progression ◽  
Murine Models ◽  
Rna Seq ◽  
Potential Therapeutic Target ◽  
Lung Cancers ◽  
Integrative Analyses

Abstract Somatic mutations of the chromatin remodeling gene ARID2 are observed in about 7% of human lung adenocarcinoma (LUAD). However, the role of ARID2 in the pathogenesis of LUAD remains largely unknown. Here we find that ARID2 expression is decreased during the malignant progression of both human and mice LUAD. Using two KrasG12D-based genetically engineered murine models (GEMM), we demonstrate that ARID2 knockout significantly promotes lung cancer malignant progression and shortens the overall survival. Consistently, ARID2 knockdown significantly promotes cell proliferation in human and mice lung cancer cells. Through integrative analyses of Chip-Seq and RNA-Seq data, we find that Hspa1a is up-regulated by Arid2 loss. Knockdown of Hspa1a specifically inhibits malignant progression of Arid2-deficient but not Arid2-wt lung cancers in both cell lines as well as animal models. Treatment with Hspa1a inhibitor could significantly inhibit the malignant progression of lung cancer with Arid2 deficiency. Together, our findings establish ARID2 as an important tumor suppressor in LUAD with novel mechanistic insights, and further identify HSPA1A as a potential therapeutic target in ARID2-deficient LUAD.

scholarly journals Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients

2016 ◽  
Vol 139 (1) ◽  
pp. 164-170 ◽  
Author(s):  
Qing-Tao Zhao ◽  
Zheng Yuan ◽  
Hua Zhang ◽  
Xiao-Peng Zhang ◽  
Hui-En Wang ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Prognostic Role ◽  
Platelet To Lymphocyte Ratio ◽  
Lung Cancers ◽  
Lymphocyte Ratio

scholarly journals The Role of Serum Cytokeratin 19 Fragment in Transarterial Infusion against Invasive Bladder Cancer

2013 ◽  
Vol 03 (03) ◽  
pp. 160-164 ◽  
Author(s):  
Ryo Takahashi ◽  
Ryoji Kimata ◽  
Shunichiro Nomura ◽  
Ichiro Matsuzawa ◽  
Yasutomo Suzuki ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Cytokeratin 19 ◽  
Transarterial Infusion ◽  
Cytokeratin 19 Fragment

scholarly journals Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations

2010 ◽  
Vol 70 (24) ◽  
pp. 10402-10410 ◽  
Author(s):  
Kunio Okamoto ◽  
Isamu Okamoto ◽  
Wataru Okamoto ◽  
Kaoru Tanaka ◽  
Ken Takezawa ◽  
...  
Keyword(s):  
Small Cell ◽  
Egfr Mutations ◽  
Egfr Inhibitor ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Induced Apoptosis

scholarly journals 85: Identification and characterization of an original mechanism of resistance to gefitinib in non-small lung cancers: role of amphiregulin

2010 ◽  
Vol 97 (1) ◽  
pp. S70-S71
Author(s):  
Busser Benoît ◽  
Lucie Sancey ◽  
Véronique Josserand ◽  
Saadi Khochbin ◽  
Jean-Luc Coll ◽  
...  
Keyword(s):  
Lung Cancers ◽  
Mechanism Of Resistance ◽  
Identification And Characterization

scholarly journals Role of the extracellular matrix in variations of invasive pathways in lung cancers

2013 ◽  
Vol 46 (1) ◽  
pp. 21-31 ◽  
Author(s):  
V.K. de Sá ◽  
L. Carvalho ◽  
A. Gomes ◽  
A. Alarcão ◽  
M.R. Silva ◽  
...  
Keyword(s):  
Extracellular Matrix ◽  
Lung Cancers

Lung Cancer After Hodgkin’s Disease: A Nested Case-Control Study of the Relation to Treatment

2001 ◽  
Vol 19 (6) ◽  
pp. 1610-1618 ◽  
Author(s):  
A. J. Swerdlow ◽  
M. J. Schoemaker ◽  
R. Allerton ◽  
A. Horwich ◽  
J. A. Barber ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Hodgkin's Disease ◽  
Case Control Study ◽  
Hodgkin’S Disease ◽  
Case Control ◽  
Lung Cancers ◽  
Number Of Cycles ◽  
Nested Case Control ◽  
Control Study

PURPOSE: To investigate the causes of the raised risk of lung cancer in patients who have had Hodgkin’s disease, and in particular the relationship to treatment. PATIENTS AND METHODS: A nested case-control study was conducted within a cohort of 5,519 patients with Hodgkin’s disease treated in Britain during 1963 through 1993. For 88 cases of lung cancer and 176 matched control subjects, information on treatment and other risk factors was extracted from hospital case-notes, and odds ratios for lung cancer in relation to these factors were calculated. RESULTS: Risk of lung cancer was borderline significantly greater in patients treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy than those who did not receive this treatment (relative risk [RR] = 1.66; 95% confidence interval [CI], 0.99 to 2.82), and increased with number of cycles of MOPP (P = .07). Exclusion of lung cancers for which histologic confirmation was not available strengthened these associations (RR = 2.41; 95% CI, 1.33 to 4.51; P = .004 for any MOPP and P = .007 for trend with number of cycles of MOPP). Risks were not raised, however, after chlorambucil, vinblastine, procarbazine, and prednisone treatment. There was evidence that the raised risk of lung cancer occurring in relation to radiotherapy was restricted to histologies other than adenocarcinoma. CONCLUSION: The results suggest that MOPP chemotherapy may lead to elevated risk of lung cancer, at least in certain subgroups of patients. The role of chemotherapy in the etiology of lung cancer after Hodgkin’s disease deserves further investigation.

scholarly journals The role of surgery in non-small-cell lung cancers

2005 ◽  
Vol 16 ◽  
pp. ii220-ii222 ◽  
Author(s):  
D.H. Grunenwald
Keyword(s):  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers
Sign in / Sign up

Export Citation Format

Share Document